Q5170 – Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg

Long description

Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg

Short description

Inj, aflibercept-boav, 1 mg

Pricing indicator

51 Drugs

Medicare coverage

C Carrier judgment – coverage decided by the Medicare contractor

BETOS category

O1E Other drugs

ASC

Approved for ambulatory surgical centers

Added

July 1, 2026

Last change

July 1, 2026 – No change

Nearby Q codes

• Q5161 – Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg
• Q5162 – Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg
• Q5164 – Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg
• Q5165 – Injection, denosumab-mobz (oziltus), biosimilar, 1 mg
• Q5166 – Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg
• Q5167 – Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg
• Q5168 – Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg
• Q5169 – Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg
• Q5171 – Injection, denosumab-mobz (boncresa), biosimilar, 1 mg
• Q5172 – Injection, filgrastim-laha (filkri), biosimilar, 1 microgram
• Q5173 – Injection, denosumab-adet (ponlimsi), biosimilar, 1 mg
• Q9001 – Assessment by chaplain services
• Q9002 – Counseling, individual, by chaplain services
• Q9003 – Counseling, group, by chaplain services
• Q9004 – Department of veterans affairs whole health partner services
• Q9950 – Injection, sulfur hexafluoride lipid microspheres, per ml